NEW YORK (GenomeWeb News) – Indian biotech services company Jubilant Biosys has entered a co-marketing agreement with DiscoveRx to screen potential drug compounds, Jubilant said yesterday.

The agreement will enable Jubilant’s pharmaceutical customers to use DiscoveRx services such as the PathHunter and CampHunter cell lines and chemiluminescent detection technology.

The agreement will also allow DiscoveRx to offer screening solutions from India, Jubilant said.

Jubilant Biosys, based in Noida with facilities in Bangalore, is a subsidiary of Jubilant Organsys.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.